Omeros’ OMS302 moves to phase III
Seattle-based biotech Omeros, said its experimental treatment for patients undergoing eye surgery to correct cataracts was safe, able to maintain pupil dilation during the procedure, and reduce postoperative pain and irritation. The results—which Omeros said will be published and presented later in a scientific forum—were from a study of 221 patients that randomly assigned people to a control group, the Omeros combination product, or its two individual components. Based on the results, the company plans to take the drug, OMS302, into phase III clinical trials.
The study showed pupil dilation was maintained through cataract surgery, and fewer people complained afterwards about moderate to severe pain. Both findings were statistically significant. Omeros didn’t say how much better the combo was than its individual components.